3,385 reports of this reaction
4.6% of all PIOGLITAZONE reports
#2 most reported adverse reaction
BLOOD GLUCOSE INCREASED is the #2 most commonly reported adverse reaction for PIOGLITAZONE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 3,385 FDA adverse event reports linking PIOGLITAZONE to BLOOD GLUCOSE INCREASED. This represents approximately 4.6% of all 74,368 adverse event reports for this drug.
PIOGLITAZONE has an overall safety score of 85 out of 100. Patients taking PIOGLITAZONE who experience blood glucose increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD GLUCOSE INCREASED is moderately reported among PIOGLITAZONE users, representing a notable but not dominant share of adverse events.
In addition to blood glucose increased, the following adverse reactions have been reported for PIOGLITAZONE:
The following drugs have also been linked to blood glucose increased in FDA adverse event reports:
BLOOD GLUCOSE INCREASED has been reported as an adverse event in 3,385 FDA reports for PIOGLITAZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD GLUCOSE INCREASED accounts for approximately 4.6% of all adverse event reports for PIOGLITAZONE, making it one of the most commonly reported side effect.
If you experience blood glucose increased while taking PIOGLITAZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.